News Snapshot:
Brattea, a Leading Renal Denervation Company in China, Completes over $US20 Million Series B+ Financing, led by Kuanping Capital 06-Apr-2021 Intellasia | PR Newswire Asia | 7:00 PM SHANGHAI , April 6, 2021 /PRNewswire/ -- Brattea, a leading renal denervation (RDN) medical technology company in China , announced today its successful completion of over $US20 million Series B+ financing led by healthcare private equity fund Kuanping Capital. New investors include Hengxu Capital, Pudong Science & Technology Co. and Brosmed. Prior round investors include Northern Light Venture Capital, BioTrack Capital, and Sherpa Healthcare Partners. The current Series B+ financing is the...
